Companies
Cibus
Companies like Cibus utilize advanced precision breeding and CRISPR to develop crops with enhanced nutritional profiles specifically for the North American food system.
- Country
- United States
Commercial
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| crop-biotech | ✓ | ✓ | ✓ | ✓ |
Regulatorsusda-aphisepaefsa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Includes $70 million Series C (2018), $22.6 million public offering (Jan 2025), and $22.3 million public offering (Jan 2026) | agfundernews.com · investor.cibus.com · last10k.com |
| Capacity | High-throughput trait production system, operational for canola, winter oilseed rape, and rice | investor.cibus.com |
| Regulatory approval | USDA-APHIS "not regulated" status for various traits; European Union approval of NGT legislation (2026); various approvals in LATAM, UK, and Canada | investor.cibus.com · ir.cibus.com · markets.businessinsider.com · sec.gov |
| Production site | San Diego headquarters; Oberlin facility (San Diego); Roseville, Minnesota facility (substantially wound down) | investor.cibus.com · ir.cibus.com |
| Headcount | Approximately 92-118 employees as of 2026 | stockanalysis.com · morningstar.com |
| Revenue | Annual revenue was $4.262 million in 2024; Q2 2026 revenue was $0.994 million | investor.cibus.com · markets.businessinsider.com · sec.gov |
Independent sources: agfundernews.com · last10k.com · markets.businessinsider.com · morningstar.com · sec.gov · stockanalysis.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biofortification of crops | crop-biotech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.